ICD G73.1ORPHA:43393LEMS

Lambert-Eaton Myasthenic Syndrome

Lambert-Eaton myasthenic syndrome is a rare autoimmune condition in which antibodies disrupt the signal passing from nerves to muscles. It causes weakness in the hips and thighs, dry mouth and reduced reflexes, and is sometimes linked to small cell lung cancer. Care includes medicines that improve nerve signalling, immune therapies and treating any underlying tumour.

172
Articles
10
Trials (1 AU)
Updated
24 September 2026
Loading...

Common Questions

What is Lambert-Eaton Myasthenic Syndrome?

Lambert-Eaton myasthenic syndrome is a rare autoimmune condition in which antibodies disrupt the signal passing from nerves to muscles. It causes weakness in the hips and thighs, dry mouth and reduced reflexes, and is sometimes linked to small cell lung cancer. Care includes medicines that improve nerve signalling, immune therapies and treating any underlying tumour.

How many clinical trials are available for Lambert-Eaton Myasthenic Syndrome?

RareWays currently indexes 10 clinical trials for Lambert-Eaton Myasthenic Syndrome, of which 2 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.

Where does the research data for Lambert-Eaton Myasthenic Syndrome come from?

RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.

Get research updates

Monthly email when new findings are published for Lambert-Eaton Myasthenic Syndrome.

No spam. Unsubscribe any time. Not medical advice.

This information is for general awareness only.

For guidance specific to your situation, please speak with your healthcare team.